Patent Protection for Pharma and Biotechnology in 2017

Topics

• Patent Protection for Pharma and Biotechnology in 2017
   

Event Details

The pharma and biotechnology industries have been affected by the recent uptick in patent rejections by the US Patent and Trademark Office (USPTO). Following the release of memorandum on Preliminary Examination Instructions in light of Alice Corp v. CLS Bank in 2014, the USPTO has been stricter in granting patent eligibility under §101. The office has begun issuing Alice rejections — including for pharma and biotech-related patents — where no previous §101 patent eligibility rejection stood. Because of the continued impact of the rejections, it is important to know how pharma and biotechnology industries should gear up for patent protection.

Organized by the Knowledge Group, this webcast will feature a panel of distinguished professionals and thought leaders who will help pharma and biotech professionals understand the important aspects of this significant topic. They will lead an in-depth discussion of patent protection for pharma and biotechnology in 2017. The panelists will also offer best practices for developing and implementing a strategic guide for the pharma and biotech industries to overcome possible rejections. 

Topics to be discussed include:

• Strategies for Overcoming and Preventing §101 Rejections in Biotech Patents
• Overview of the 2014 US Supreme Court Decision on Alice Corp. v. CLS Bank
• 35 USC 101 in light of Alice
• Requirements in § 101Developments in the biotech/pharma arena since Alice: focus on RLM v. CellzDirect and Sequenom v. Ariosa
• Steps in Assessing Patent Eligibility for Pharma and Biotech
• Understanding how Examiners are thinking about the process